Gastric cancer remains a highly prevalent malignancy worldwide, with surgical resection currently constituting the cornerstone of treatment aimed at improving long-term patient survival. Owing to their notable advantages, including reduced surgical trauma and accelerated postoperative recovery, minimally invasive procedures are progressively supplanting conventional open surgery and have become the mainstream approach in gastric cancer management. Concurrently, the rapid advancement of artificial intelligence (AI) technologies has enabled real-time intraoperative monitoring of surgical scenes, thereby furnishing novel technical support for adjunctive decision-making, surgical navigation, and skill assessment during gastrectomy. This article provides a systematic review of the current status of AI applications in minimally invasive gastric cancer surgery, with a particular focus on research progress pertaining to instrument recognition, surgical phase identification, delineation of normal anatomical structures, detection of metastatic foci, and early warning of intraoperative adverse events. Furthermore, we discuss the potential value of AI in enhancing surgical efficiency, ensuring patient safety, and optimizing surgical education. On this basis, we further analyze the principal challenges and inherent risks confronting current AI systems, with the aim of informing future technological innovation and facilitating clinical translation.

With the rapid development of antibody genetic engineering, bispecific antibody technology has been advanced. They are capable of binding two or more different epitopes simultaneously, thus offering specific advantages over natural monoclonal antibodies in immunotherapy. Bispecific antibodies have been successfully used in cancer therapy (e.g. melanoma, Hodgkin's lymphoma, liver cancer, and stomach cancer) and inflammation therapy (e.g. rheumatoid arthritis, psoriasis and Crohn's disease), but are still in their early stage for viral immunotherapy. In this study, we reviewed the research progress of bispecific antibodies for immunotherapy of virus infections, especially those with good effects in vivo and in vitro, to provide references for the research and development of bispecific antibodies for antivirus treatment.
Antibodies, Bispecific ; therapeutic use ; Antibodies, Monoclonal ; Epitopes ; Humans ; Immunotherapy ; Virus Diseases

Objective To approach therapeutic effect of captopril combined with amiodarone in treating acute myocardial infarction complicating atrial fibrillatio. Methods Select acute myocardial infarction complicating atrial fibrillatio 62 patients, divide into two groups, therapy bundle offer captopril combine amiodarone, control bundle offer propafenone, compare rate of atrial fibrillatio turn over with 24 houres, control rate of atrial fibrillatio attack (reduce atrial fibrillatio attacking over 60%), tetain sinus rhythn, backward heart failure incidence rate, repeated infarct rate, hospitalization death rate, death rate one year later, stroke incidence rate within one year. Results Captopril combined with amiodarone in treating acute myocardial infarction complicating atrial fibrillatio, it can turn over atrial fibrillatio utility, control atrial fibrillatio attack (reduce atrial fibrillatio attacking over 60%), reduce repeated infarct rate (6.3% vs 16.7%), death rate (9.4% vs 16.7%), backward heart failure incidence rate (9.4% vs 30.0%), stroke incidence rate (3.1% vs 13.3%)(all P<0.01). Conclusions The therapeutic effect is certain about captopril combine amiodarone in treating acute myocardial infarction complicating atrial fibrillatio. And this method is safety. The patient profit from it in many ways. It deserves generalization and application.